Member of Lyonbiopole
For more than a century, Aguettant has developped, manufactured and marketed essential drugs for hospitals. Our specialty areas are:
- anaesthesia, intensive care and emergency medicine;
- parenteral nutrition;
- the treatment of movement disorders due to Parkinson's disease;
- infusion and rinsing solutions.
With sales around €230 M and 1000 employees, the Aguettant Group develops several unique know-hows:
- ready-to-use pre-filled syringes, ideal for emergency medicine and hospital settings;
- pen for self-injection at home;
- trace elements in injectable solutions;
- through Aguettant Diagnostics and Promise Proteomics, subsidiaries of the Aguettant Group, the development and production of in-vitro diagnostic kits in the fields of biotherapy monitoring and CBRN detection.
Strategic application domain: Human Medicine
Application market: Intensive care medicine, Neurology & Mental Health Disorders, Others
Type of activity: Diagnostics, Medical device, Therapeutics, Pharma or Biotech
Technologies: Analytical methods, diagnostic & Pronostic markers, Drug delivery device & Technologies, Genomics & Proteomics, Biochips
Created on jan. 1st, 1900 - 1000 employees
Address
1 rue Alexander Fleming 69007 LYON
Vous devez être connecté et membre de Lyonbiopôle pour voir les contacts.